Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OsteoActivator-C
- Development stage
- Discontinued
- Lead developer
- Osteo Pharma
- Modality
- Small Molecules
- Administration
- Implant
01
Overview
OsteoActivator-C is a drug-device combination product developed by Osteo Pharma. It consists of orthopedic implants (such as screws) coated with a proprietary biodegradable PLGA-based coating that provides local, sustained release of testosterone and alendronate. This combination therapy is designed to enhance the osseointegration of orthopedic implants and treat bone defects. Testosterone acts locally to promote osteoblast-mediated bone formation, while alendronate inhibits osteoclast-mediated bone resorption. Together, they work synergistically to increase bone-implant contact and adjacent bone formation, preventing implant loosening. The product is currently in preclinical development.
- Brand names
- OsteoActivator-C
- Other names
- OsteoActivator C
02
Targets
AR (Adrenergic receptors)FDPS (Farnesyl pyrophosphate synthase)
Beyond the preview
Go deeper on OsteoActivator-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OsteoActivator-C.